Graphical Abstract Highlights d Stress induces Vms1 mitochondrial localization independently of protein interaction d Ergosterol peroxide (EP) binding mediates Vms1 mitochondrial localization d The Vms1 leucine-rich sequence (LRS) binds the mitochondrial targeting domain (MTD) d The LRS competes with EP for MTD binding to inhibit Vms1 mitochondrial localization SUMMARY
In Brief
Vms1 translocates to damaged mitochondria in response to stress by unknown mechanisms. Here, Nielson et al. demonstrate that Vms1 mitochondrial translocation is regulated by a hydrophobic intramolecular interaction and the accumulation of an oxidized sterol, ergosterol peroxide. This study implicates sterol oxidation as a mechanism for mitochondrial stress response.
INTRODUCTION
Many critical cellular activities depend on mitochondria, including bioenergetics, biosynthesis, and signaling (Calvo and Mootha, 2010) . Therefore, it is not surprising that mitochondrial dysfunction is a hallmark of a wide variety of diseases and disorders, including neurodegeneration and heart disease (Lin and Beal, 2006) . Major effectors of mitochondrial dysfunction are the reactive oxygen species (ROS) that result from inefficiencies in the electron transport chain (Circu and Aw, 2010) and can lead to DNA damage, protein misfolding and aggregation, altered membrane permeability, disturbed Ca 2+ homeostasis, disrupted oxidative phosphorylation, and, eventually, cell death (Zorov et al., 2014) .
To combat these deleterious outcomes and maintain mitochondrial function and integrity, cells use a network of mitochondrial quality control systems. One of these is the ubiquitin-proteasome system (UPS), which can remove and degrade proteins from the mitochondrial outer membrane (MOM). Ubiquitylated MOM proteins, such as the mitofusins (e.g., Mfn1 and Mfn2) (Tanaka et al., 2010) and TOM complex subunits (e.g., Tom40 and Tom70) (Yoshii et al., 2011) , are extracted by the AAA-ATPase p97/VCP (Livnat-Levanon and Glickman, 2011) and targeted for degradation by the cytoplasmic 26S proteasome (Heo and Rutter, 2011) .
Previously, we showed that cytoplasmic Vms1 (VCP/Cdc48associated mitochondrial stress-responsive 1) serves as an adaptor to promote the mitochondrial localization of Cdc48, the S. cerevisiae p97 homolog, and its cofactor Npl4 when cells are exposed to mitochondrial stressors such as antimycin, oligomycin, and H 2 O 2 (Heo et al., 2010) , as well as paraquat and DMNQ (unpublished data). In the absence of the Vms1-Cdc48 complex, cells accumulate ubiquitylated mitochondrial proteins, suffer progressive mitochondrial failure, have elevated levels of mitophagy, and fail to survive under mitochondrial stress conditions (Heo et al., 2010) .
Vms1 translocation from the cytosol to mitochondria under conditions of mitochondrial stress requires its highly conserved mitochondrial targeting domain (Vms1 MTD ) (Heo et al., 2013) . Vms1 MTD localization to mitochondria in unstressed conditions is prevented by an intramolecular interaction with the Vms1 N-terminal leucine-rich sequence (Vms1 LRS ). In the absence of the Vms1 LRS , Vms1 MTD constitutively localizes to mitochondria in the presence or absence of stress (Heo et al., 2013) , suggesting that translocation of the full-length protein is regulated by this intramolecular interaction. Localization is also regulated by mitochondrial damage because full-length wild-type Vms1 localizes to damaged, but not undamaged, mitochondria, indicating that damaged mitochondria are specifically marked for Vms1 recruitment (Heo et al., 2013) .
These data prompt several questions: First, how does the Vms1 LRS inhibit localization of the Vms1 MTD to mitochondria? Second, what is (are) the mitochondrial molecule(s) that mediate Vms1 MTD binding to mitochondria? Third, what is the stress signal that modifies mitochondria and/or Vms1 to promote Vms1 translocation to damaged mitochondria? Herein, we describe a mechanism whereby Vms1 localization to mitochondria results from interaction with the stress-induced oxidized sterol ergosterol peroxide, the binding of which is opposed by the intramolecular Vms1 LRS-MTD association.
RESULTS

Vms1 Crystal Structure Shows the LRS Binding a Hydrophobic Groove on the MTD Surface
To further understand the intramolecular regulation of Vms1 localization to mitochondria, we visualized the Vms1 LRS-MTD interaction by determining a crystal structure of Vms1 LRS-ZnF-MTD ( Figure 1A ). Many constructs of S. cerevisiae Vms1 were prepared by expression and purification from E. coli and subjected to crystallization trials. The crystalized construct comprised residues 1-417 and lacked residues 38-69, which are poorly conserved and were predicted to form an unstructured loop (Figure 1A) . Removal of this loop had no effect on Vms1 function in vivo ( Figure S1 ). The structure was determined using singlewavelength anomalous diffraction from the selenomethioninesubstituted protein and was refined at a resolution of 2.7 Å to R work /R free values of 18.7%/24.5% (Table 1 ).
The Vms1 model comprises the LRS (residues 13-35), portions of the ZnF domain including the Zn 2+ ion and its coordi- Black line below indicates the crystallized construct. LRS, leucine-rich sequence; ZnF, zinc finger; MTD, mitochondrial targeting domain; AnkR, ankryin repeat; CC, coilcoil; VIM, VCP-interacting motif. Grayed out areas, including all segments between domains, denote regions not visible in the electron density maps. (B) Vms1 LRS-ZnF-MTD ribbon representation. The Zn ion is represented by a gray sphere. Dashed lines indicate residues not visible in the structure, except for the large segments 36-73 and 107-187, the ends of which are labeled with residue numbers. (C) Alignment of LRS residues visible in (B). White letters with gray background indicates similarity. White letters with a black background indicates identity. Yellow asterisks indicate Leu residues whose mutation abolished MTD interaction (Heo et al., 2013) . (D) LRS Leu 23, 28, 31, and 33 (yellow), the same residues marked by asterisks in (C), are shown explicitly on the Vms1 ribbon representation. The MTD is shown as a surface representation, colored by Kyte-Doolittle (K-D) hydrophobicity (Kyte and Doolittle, 1982) . (E) Alignment of MTD hydrophobic groove that contacts the LRS. Conservation is colored as in (C). Blue asterisks indicate residues shown in (F). (F) Ribbon representation showing the interaction between the MTD and LRS on the left. Side chains are shown for hydrophobic residues in each domain that are buried at the LRS-MTD interface. The LRS is removed on the right to better visualize the MTD residues. See also Figure S1. nating residues (residues 74-80 and 90-106), and the majority of the MTD (residues 188-197, 203-257, 267-286, and 318-397) (Figure 1B ). No other residues in the Vms1 LRS-ZnF-MTD construct are visible in the crystal structure, presumably because they are highly mobile or because they were excised by the low level of protease that we found to be necessary to grow crystals ( Figure 1A ). The Vms1 MTD adopts a fold in which a mixed b sheet is flanked on both sides by a helices (Figure 1B) . Comparison with structures in the PDB by the DALI server (Holm and Rosenströ m, 2010) indicated that the MTD fold is most closely related to eukaryotic peptide chain release factor subunit 1 (3e1y-C), although the overlap is only on 117 pairs of Ca atoms and gives a large root-mean-square deviation (5.7 Å ) .
LRS and MTD Mutations that Disrupt the LRS-MTD Interface Alter Mitochondrial Localization
The LRS (residues 13-35) packs against the MTD through an interface that includes LRS residues that are hydrophobic and conserved. The N-terminal helix (residues 14-18) is not highly conserved ( Figure 1C ). Conserved hydrophobic residues follow in an extended turn (residues 19-24) that are buried against the MTD ( Figure 1C ; Ile20, Phe21, and Leu23). This is followed by a second helix (residues 25-30) that includes two conserved Leu residues that are partially buried. Lastly, residues 31-35 constitute a short loop containing highly conserved and buried Leu residues ( Figure 1C ; Leu31 and Leu33). The only residue in the entire LRS that is conserved and not buried is Ser35. We previously identified the conserved Leu residues (Leu23, Leu28, Leu31, and Leu33) in the LRS as being important for the interaction with the MTD (Heo et al., 2013) ( Figure 1C ). Our structure revealed that these residues mediate multiple hydrophobic inter-domain contacts at the LRS-MTD interface ( Figure 1D ). Moreover, mutation of these LRS Leu residues led to greater mitochondrial localization of Vms1 (Heo et al., 2013) , which suggests that displacement of the LRS may unmask a surface of Vms1 that is important for binding to a mitochondrial receptor and/or the mitochondrial membrane.
The MTD surface buried by the LRS is a large (1,205 Å 2 ) groove that is predominately composed of hydrophobic residues that contact the conserved LRS hydrophobic residues ( Figure 1D ). The majority of these hydrophobic MTD residues reside in two strands (residues 190-194 and 203-207) , although Leu210, Leu223, and Leu392 also contribute ( Figures 1E and 1F) . A few hydrophilic residues, which are not conserved, also lie at the LRS/MTD interface (Asn227, His253, and Arg255).
Guided by the structure, we further explored the importance of residues at the LRS-MTD interface and across the MTD surface for mitochondrial localization by determining the localization of Vms1-GFP in S. cerevisiae when 19 conserved MTD residues were substituted individually or in clusters. Localization was tested in the context of the Vms1 MTD -GFP construct because its constitutive and robust mitochondrial localization simplifies a quantitative comparison between mutants. We identified several mutants that displayed impaired mitochondrial localization of the Vms1 MTD -GFP fusion protein and others that did not (representative examples are shown in Figures 2A and 2B ; a summary is shown in Figures 2D and 2E ). The reduction in mitochondrial localization did not result from a reduction in protein abundance because the abundance of each mutant is similar to that of wild-type ( Figure 2C ).
Building on the earlier mutational study of conserved LRS Leu residues (Heo et al., 2013) , we verified that the MTD residues that are located at the LRS-MTD interface are also important for LRS-MTD binding in solution. This was done by mutating the MTD residues Phe193 or Ile204, which are buried against the LRS ( Figures 2D and 2E ). In both cases, co-expression of these mutated MTD-GFP constructs with an LRS-hemagglutinin (HA) construct showed impaired interaction in co-immunoprecipitation experiments ( Figure 2F ). Interestingly, these mutants exhibited reduced mitochondrial localization (Figures 2A and 2B ). This is in contrast to the analogous mutations of hydrophobic residues on the LRS side of the interface, which also showed reduced LRS-MTD interaction but displayed increased mitochondrial localization (Heo et al., 2013) . These observations are consistent with the model that the LRS masks MTD residues that are important for mitochondrial localization, so that mutation of LRS residues that disrupt the MTD interaction uncovers a surface that promotes mitochondrial localization, whereas mutation of MTD residues that disrupt the LRS interaction might also disrupt a part of the MTD surface that mediates mitochondrial localization.
MTD Surface Residues Close to the LRS Are Also Important for Mitochondrial Localization Our survey of residues across the MTD surface revealed a number of mutants that are not buried at the LRS interface yet displayed >10% reduced mitochondrial localization (Figures 2C and 2D) . These residues were all from the region surrounding the Vms1 LRS interaction interface, whereas mutations elsewhere had little or no effect on Vms1 localization (Figures 2A and 2B ). For example, Y190D and K194D/K196D, which are within 10 Å of the LRS but are not at the LRS interface and display normal interaction with the Vms1 LRS , showed >10% reduced localization to mitochondria (Figures 2A, 2B , and 2F). The observation that MTD residues both at and surrounding the LRS interface mediate MTD localization to mitochondria suggests that the localization of Vms1 to mitochondria involves remodeling of j and jF c j are the observed and calculated structure factor amplitudes, respectively, summed over structure factors used in refinement calculations d R free = R factor calculated using a random set of reflections (5% of total) that were not used in refinement calculations the structure to displace the LRS and form a mitochondrial binding surface formed by multiple MTD residues that are either surface exposed or buried at the LRS interface in the Vms1 crystal structure.
Vms1 Binds Mitochondria via a Lipid Species
To better understand how the stress-responsive translocation of Vms1 to mitochondria is regulated, we sought to identify the molecule(s) to which the Vms1 MTD binds on the MOM. We initially hypothesized that Vms1 mitochondrial binding is mediated by a protein, and we screened for a reduction of Vms1 MTD localization in over 500 genetic mutants, each lacking a unique gene encoding a non-essential, nuclear-encoded mitochondrial protein . None of the mutant strains displayed a substantial reduction of Vms1 MTD localization to mitochondria (data not shown). Recognizing that Npl4 and other Cdc48 adaptor proteins bind ubiquitin to recruit Cdc48 to ubiquitylated substrates (Schuberth et al., 2004; Ye et al., 2003) , we hypothesized that Vms1 might also bind (poly)ubiquitin at the mitochondrial surface. However, we observed that treating mitochondria with the Usp2 deubiquitylating enzyme had no effect on Vms1 interaction with mitochondria (data not shown).
To determine whether any mitochondrial surface protein is required for Vms1 binding, we treated purified mitochondria with Proteinase K. After digestion, we observed efficient degradation of cytosol-exposed mitochondrial proteins (e.g., Tom22 and Fzo1) but very little cleavage of MOM-imbedded (e.g., Por1) and intra-mitochondrial proteins (e.g., Sdh1, Sdh2, and Mia40), suggesting that mitochondrial surface protein had been thoroughly digested without compromising mitochondrial integrity (Figure 3A) . Surprisingly, we observed no significant difference in Vms1 affinity toward mitochondria after Proteinase K treatment ( Figures 3B and 3C ). Although we cannot rule out the possibility that Proteinase K-resistant proteins or loops contribute to Vms1 binding, these results suggested that mitochondrial surface proteins are dispensable for Vms1 binding to mitochondria.
Because MOM protein appears to be dispensable for Vms1 binding, we hypothesized that Vms1 binds mitochondrial lipids. The majority of mitochondrial lipids are phospholipids, with much smaller quantities of sphingolipids and sterols principally (A) vms1D cells expressing the indicated Vms1 MTD -GFP construct and mitochondria-targeted red fluorescent protein (RFP) were grown to mid-log phase and analyzed by fluorescence microscopy. Representative images are shown. DIC, differential interference contrast. (B) The mitochondrial MTD-GFP intensity from (A) was quantified as described for 100+ cells in each strain over multiple days of imaging. Error bars, mean ± SEM. (C) Cells from (A) were lysed as described and analyzed by western blot. (D) Table of MTD residues mutated, with quantified mitochondrial localizations relative to wild-type (WT) (% ± SEM) and p values indicated. Residues were initially mutated in pairs or triplets and only made as single mutants if there was a greater than 10% reduction in MTD localization. Some mutants enhanced mitochondrial localization, indicated by values greater than 1. The far-right column gives the percent increase in relative Å 2 surface exposure of each amino acid in the MTD alone versus the LRS-MTD complex, based on assuming no conformational change upon removing the LRS from the crystal structure. (E) Ribbon/surface overview of Vms1 MTD with mutated residues highlighted. Residues whose mutation exhibited >10% reduction (red) and %10% reduction (green) in MTD localization are indicated. (F) The vms1D strain was transformed with Vms1 1-182 -HA and the indicated Vms1 MTD -GFP construct. Strain lysates were immunoprecipitated with anti-HA antibody. Western blots were performed with anti-HA and GFP antibodies. constituting the remainder. Recent studies have described unique roles for both phospholipids (Chu et al., 2013) and sphingolipids (Huang et al., 2012) in recruiting components of the mitophagy machinery to mitochondria. Due to their reactive phosphodiester linkage, phospholipids are susceptible to hydrolysis by mild base, whereas sphingolipids and sterols are not . We took advantage of this property to create liposomes containing total mitochondrial lipids or liposomes containing a lipid extract that lacked phospholipids. Vms1 bound liposomes containing total mitochondrial lipids, and this binding was enhanced with lipid extract that lacked phospholipids (Figure 3D) . The increased level of binding seen upon hydrolysis and removal of the more abundant phospholipids may result from increased local concentration and liposome incorporation of sterols/sphingolipids. These observations indicate that Vms1 binds a sterol or sphingolipid species.
To identify which specific lipid was responsible for Vms1 binding to mitochondria, we assayed for Vms1 binding to high-per- (D) Floatation assay results for control liposomes and liposomes supplemented with mitochondrial lipids. For liposomes containing mitochondrial lipids, we added lipids isolated from 1 mg mitochondria (determined by measuring protein concentration) per 100 mL liposomes. Purified mitochondrial lipids were added either without modification or following akaline-treatment to generate alkaline-resistant mitochondrial lipids. (E) Floatation assay results obtained with liposomes prepared with ultra-performance liquid chromatography (UPLC) fractions of purified mitochondrial lipids (lipids from 2 mg mitochondria per 100 mL liposomes). (F) Fraction 2 in (E) was sub-fractionated, and resulting lipid fractions were incorporated into liposomes (lipids from 1 mg mitochondria per 100 mL liposomes) and subjected to a floatation assay. (G) Mitochondrial alkaline-resistant lipids were separated into five fractions by TLC. Lipids isolated from each fraction were incorporated into liposomes (lipids from 1 mg mitochondria per 100 mL liposomes) and subjected to a floatation assay. (H) Lipids from the five UPLC sub-fractions (F) and the five TLC fractions (G) were analyzed by TLC and orcinol stain. The star indicates the common species with formula C 28 H 44 O 3 . formance liquid chromatography (HPLC) and thin-layer chromatography (TLC)fractionated, alkaline-resistant mitochondrial lipids. Sequential, orthogonal fractionation enabled the isolation of two lipid mixtures with highly enriched Vms1 binding activity ( Figures 3E-3G ). We used TLC to compare lipids found in the two purified fractions that displayed the strongest binding activity toward Vms1, and we identified a single lipid species that was specifically enriched in both fractions ( Figure 3H ). In parallel, analysis of these binding and adjacent non-binding fractions by liquid chromatography-mass spectrometry (LC-MS) identified a single specific candidate species with a mass corresponding to the molecular formula C 28 H 44 O 3 .
Ergosterol Peroxide Is Necessary and Sufficient for Vms1 Localization to Mitochondria
The molecular formula C 28 H 44 O 3 corresponds to hundreds of lipid species. To determine the molecular structure of the Vms1-binding lipid, we used silica gel column chromatography to purify a large quantity of the lipid, which we subjected to multiple structural analyses. As expected, the apparent binding activity toward Vms1 increased as C 28 H 44 O 3 was purified (Figures 4A and 4B) , consistent with C 28 H 44 O 3 mediating Vms1 binding. We obtained a 1 H-NMR (nuclear magnetic resonance) spectrum of the isolated ligand ( Figure 4C ) and compared the peaks with published NMR spectra (Nowak et al., 2016) . From this comparison, we determined that the peaks in the NMR spectra of our purified ligand were identical to those of ergosterol peroxide (EP), which has the same C 28 H 44 O 3 formula. Furthermore, our purified ligand and commercial EP possess identical retention factors by TLC ( Figure 4D ), identical retention times by LC-MS ( Figure 4E ), and equivalent tandem MS (MS/MS) spectra at multiple collision energies . In combination, these data indicate that the C 28 H 44 O 3 lipid species that we isolated on the basis of its direct Vms1 binding activity is EP.
EP is an oxidized sterol, structurally differing from ergosterol only by the presence of an endoperoxide. We found that Vms1 displayed comparable binding to nitrocellulose-spotted com-mercial EP and the purified C 28 H 44 O 3 , while displaying no affinity toward ergosterol ( Figure 4G ). EP is generated when highly reactive singlet oxygen and the conjugated 5,7-diene of ergosterol spontaneously cyclize, in a [4+2] Diels-Alder type cycloaddition, to generate the 5,8-endoperoxide ( Figure 4H ). Ergosterol is found in many membranes throughout the cell. However, we found that EP levels were specifically enriched at mitochondria relative to other cellular membranes ( Figures 4I, 4J , and S4D), which is consistent with the hypothesis that EP recruits Vms1 selectively to mitochondria.
Because EP is non-enzymatically produced from ergosterol and ROS, we tested the necessity of EP for mitochondrial localization of Vms1 by eliminating these precursors. The importance of ROS was demonstrated by observing a significant reduction in Vms1 MTD localization to mitochondria in cells grown in anoxic conditions compared with cells grown in normoxia (Figures 5A and 5B) , with no change in Vms1 MTD -GFP abundance (Figure S3A ). Production of ergosterol, the other essential EP precursor, occurs through the mevalonate pathway, which is inhibited by the statin class of drugs. Statins (e.g., mevastatin) competitively inhibit HMG coenzyme A (CoA) reductase, the rate-controlling enzyme of the mevalonate pathway. We observed a significant reduction in Vms1 MTD localization to mitochondria upon mevastatin treatment ( Figures 5C and 5D) , with no effect on the steady-state abundance of Vms1 MTD -GFP (Figure S3B) . Thus, the EP precursors, ergosterol and oxygen/ROS, are both necessary for normal Vms1 MTD localization to mitochondria.
Although sterol synthesis is essential for cell survival, some steps in the ergosterol biosynthetic pathway are not essential in S. cerevisiae. Loss of those steps leads to the synthesis of ergosterol-like species that are capable of fulfilling the essential functions of ergosterol (Bö cking et al., 2000) but may be differentially capable of mediating Vms1 mitochondrial localization. To test this possibility, we measured Vms1 MTD -GFP localization to mitochondria (Figures 5E and 5F) and mitochondrial ergosterol and EP levels ( Figures 5G and 5H ) in strains lacking non-essential ergosterol biosynthetic genes. The specific ''ergosterol'' or ''EP'' species in these mutant strains are likely unique to each strain and are, therefore, indicated as ergosterol* and EP*. Vms1 MTD localization to mitochondria was most affected in erg2D, erg3D, erg5D, and erg24D mutants. Erg2 and Erg3 catalyze the formation of the 7,8 and 5,6-alkenes, respectively (Figure 5I) , which constitute the 5,7-diene required for EP formation (Veen and Lang, 2005) , while the desaturase Erg5 and reductase Erg24 catalyze reactions near the 5,7-diene ( Figure 5I ) (Veen and (J) Vehicle, 3.75 mg ergosterol, or 3.75 mg ergosterol peroxide was added to mitochondrial lipids isolated from 300 mg WT or erg2D cells to make liposomes as described (STAR Methods) for use in the floatation assay. (K) Vms1 binding to liposomes from (J) was quantified as the ratio of bound Vms1 to input Vms1 and normalized to liposomes containing no added lipids for each strain. Error bars, mean ± SEM. **p % 0.01. See also Figure S3 . Lang, 2005) . In contrast, Vms1 MTD localization and mitochondrial EP* levels were only mildly affected in the absence of the reductase Erg4, methyltransferase Erg6, and glucosyltransferase Atg26. None of these mutants had a significant effect on Vms1 MTD -GFP abundance ( Figure S3C ). These data, therefore, indicate that Vms1 MTD localization to mitochondria is dependent on ergosterol biosynthesis and, particularly, on the availability of the 5,7-diene that becomes oxidized to form EP.
To determine whether EP is sufficient to promote Vms1 binding to lipid membranes, we tested the impact on Vms1 binding of introducing EP or ergosterol into liposomes prepared from mitochondrial lipids. We used mitochondrial lipids obtained from erg2D cells because this strain exhibited decreased Vms1 MTD localization to mitochondria and reduced levels of EP without grossly affecting the abundance of ergosterol-like sterols ( Figures 5G and 5H ). Exogenous addition of EP to erg2D mitochondrial lipids restored Vms1 binding, while the addition of ergosterol had no effect ( Figures 5J and 5K ). Taken together, these observations indicate that EP is necessary and sufficient for Vms1 binding to mitochondria and mitochondriaderived lipids.
Stress Stimulates Mitochondrial EP Abundance
Having determined that EP binds Vms1 and is necessary for Vms1 localization to mitochondria, we next sought to determine whether EP serves as a stress signal to recruit Vms1 specifically to damaged mitochondria. This idea is supported by our previous observation that Vms1 preferentially localizes to mitochondria in vivo that have been selectively damaged by Killer Redgenerated ROS (Heo et al., 2013) . Because mitochondria in the same cell that were not damaged by laser activation of the Killer Red did not show localization of Vms1, we concluded that the stress signal that promotes Vms1 translocation is confined to damaged mitochondria. To further test this hypothesis, we evaluated the in vitro interaction between Vms1 and mitochondria independently isolated from both stressed and unstressed cells.
As predicted from the model that stressed mitochondria display enhanced Vms1 binding, we observed that mitochondria isolated from cells stressed with either rapamycin-which, among other things, induces endogenous ROS (Kissová et al., 2006 )or H 2 O 2 have an increased affinity toward Vms1 in vitro, compared with mitochondria from unstressed cells. Conversely, Vms1 purified from stressed (rapamycin or H 2 O 2 ) and unstressed cells exhibited identical mitochondrial binding in vitro (Figures 6A  and 6B ). This suggests that the stress-induced changes that promote Vms1 localization are localized to mitochondria.
We further demonstrated that the stress-induced change that recruits Vms1 is displayed within the mitochondrial lipid fraction by using an in vitro liposome-floatation binding assay. Consistent with previous results, we observed that Vms1 exhibits enhanced affinity toward liposomes prepared from mitochondrial lipids isolated from stressed cells ( Figures 6C and 6D) . The simplest explanation of these data is that elevated ROS causes elevated EP abundance, which recruits Vms1 to mitochondria. This model was further supported by our finding of elevated EP levels in mitochondrial lipids isolated from cells that had been treated with either rapamycin or H 2 O 2 ( Figures  6E and 6F) .
Vms1 LRS and EP-Containing Membranes Compete for Vms1 MTD Binding
To test the hypothesis that the Vms1 LRS and EP-containing (EP + ) membranes compete for binding with the Vms1 MTD , we used the LRS mutant ''L4A,'' in which four of the LRS-buried leucines are changed to alanine, which we previously showed disrupted the Vms1 LRS/MTD interaction and promoted constitutive localization to mitochondria (Heo et al., 2013) (Figure 7A ). In floatation assays, Vms1 L4A bound EP + liposomes substantially more strongly than Vms1 WT did, particularly as the amount of liposomes in the assay was decreased ( Figures 7B and 7C ), thereby validating that disruption of the Vms1 LRS/MTD interaction enhances Vms1 binding to EP + liposomes.
Given that disrupting the Vms1 LRS/MTD interaction promoted EP + membrane binding, we postulated that restricting Vms1 LRS/MTD dissociation would reduce membrane binding. To test this idea, we engineered a Vms1 protein in which Vms1 LRS and Vms1 MTD can be tethered via chemical crosslinking and are thereby stabilized against dissociation. To crosslink Vms1 with the sulfhydryl-specific bismaleimidohexane (BMH), we introduced a single Cys in the Vms1 LRS and a single Cys in the Vms1 MTD (Vms1 Cys-Cys -HA) so that the two Cys residues would be in close proximity ( Figure 7D ). C387, the only reactive Cys residue in the Vms1 LRS/MTD construct, was mutated to Ala in the Vms1 Cys-Cys constructs. All Vms1 Cys-Cys mutants were fully functional in vivo (data not shown). To monitor crosslinking, we introduced a PreScission protease site in a loop N-terminal to the Vms1 MTD so that migration on SDS-PAGE could distinguish the crosslinked species ( Figure 7E ). Importantly, protease cleavage of purified Vms1 did not alter migration on gel filtration chromatography, which indicates that the two cleaved Vms1 fragments maintained a stable association under the solution conditions used and that the structure is not grossly distorted. Cleaved Vms1 WT or Vms1 Cys-Cys was incubated with DMSO or BMH crosslinker and analyzed by SDS-PAGE. Crosslinking was incomplete, but an identifiable crosslinked species appeared only in the Vms1 Cys-Cys protein subjected to BMH ( Figure 7E ). Incomplete crosslinking enabled us to compare crosslinked and non-crosslinked protein within a single floatation assay. Three separate Vms1 Cys-Cys proteins were probed for their ability to bind EP + liposomes, and all three were found to exhibit a reduced ratio of crosslinked:non-crosslinked Vms1 in liposome-bound fractions compared to input (Figures 7E and 7F ). This indicates that crosslinked Vms1 Cys-Cys , in which the LRS-MTD interaction is stabilized, binds EP + membranes less efficiently than a cleaved version of the same protein in which the LRS-MTD interaction is not stabilized. These data suggest that dissociation of the Vms1 LRS/MTD interaction is required for efficient Vms1 binding to EP + membranes.
Next, we wanted to determine the fate of the LRS when the MTD binds an EP + lipid membrane. Based on our previous results, we predicted that the LRS would dissociate from the MTD upon lipid binding. To test this model, we designed a GFP-Vms1-HA construct that contained a PreScission protease site immediately C-terminal to the LRS ( Figure 7G ) and followed the binding of the GFP-LRS and MTD-HA in a floatation assay. Cleavage of this Vms1 construct with PreScission protease did not alter migration on gel filtration chromatography ( Figures 7H and 7I) , indicating that the Vms1 LRS/MTD interaction remained intact, as observed previously. We quantified binding of the full-length construct (GFP-Vms1-HA) and the two halves of the cleaved construct (GFP-LRS/MTD-HA) to EP + liposomes in a floatation assay ( Figure 7J) . The difference in binding affinity was quantified as the ratio of GFP-LRS:GFP-Vms1 or MTD-HA:Vms1-HA in the bound and unbound fractions ( Figure 7K ). GFP-Vms1 bound more strongly than GFP-LRS, while MTD-HA bound more strongly than Vms1-HA, thereby indicating that LRS association diminishes MTD membrane-binding activity. Taken together, these three observations strongly support a model wherein the LRS and EP + lipid membranes compete for binding to the MTD.
Finally, we wanted to determine the effect of mutating the MTD on EP + liposome binding. Based on our model, we predicted that mutations that disrupt the LRS/MTD interface would promote membrane interaction, while mutants that maintain the LRS/ MTD interaction but reduce mitochondrial localization will reduce membrane interaction. To test this model, we purified the mutants described in Figure 2 in the context of His 12 -Vms1 1-417 and quantified binding to EP + liposomes ( Figure S4 ). K194D/K196D, a mutant with reduced mitochondrial localization that maintains LRS interaction, had significantly reduced binding to liposomes ( Figure S4 ). The other mutants maintained or increased membrane interaction, which supports the model that disrupting the LRS-MTD interaction increases EP + mem-brane binding in vitro, regardless of how the mutant behaves in vivo.
DISCUSSION
This study set out to answer two questions. First, we sought to discover how the Vms1 LRS inhibits localization of Vms1 to mitochondria. We had previously described that a highly conserved region of Vms1 (MTD) was necessary and sufficient for localization to mitochondria (Heo et al., 2013) . Additionally, we showed that an LRS bound the MTD and inhibited localization to mitochondria (Heo et al., 2013) . The crystal structure of Vms1 demonstrates that the LRS leucine residues, whose mutation we have shown disrupts LRS binding to the MTD and de-represses Vms1 localization to mitochondria (Heo et al., 2013) , line a conserved hydrophobic groove on the MTD. Guided by the Figure S4 . structure, we now show that mutation of hydrophobic MTD residues at the LRS interface also disrupts LRS binding while diminishing MTD mitochondrial localization. Taken together, these structural and mutagenic data support the model that the LRS inhibits Vms1 localization to mitochondria through direct, hydrophobic interactions with the MTD and that displacement of the LRS uncovers the mitochondrial binding surface.
Second, we sought to discover the mitochondrial molecule(s) responsible for mediating Vms1 MTD localization to mitochondria. Despite extensive effort, we failed to identify a mitochondrial protein that was important for Vms1 MTD localization. We did, however, identify and characterize EP as a mitochondrial membrane lipid that is necessary for Vms1 mitochondrial localization. We demonstrated that Vms1 directly binds EP and that increasing EP abundance is sufficient to enhance Vms1 binding to membranes. We also found that EP is necessary for MTD localization to mitochondria in vivo, as we observed decreased localization when EP precursors were reduced or the ergosterol biosynthetic pathway was disrupted. Lastly, we showed that stress conditions that promote Vms1 translocation to mitochondria (rapamycin or H 2 O 2 ) also lead to increased mitochondrial EP abundance and that the increase in EP correlates with increased Vms1 binding to lipids purified from mitochondria. Taken together, these observations indicate that EP is a necessary and sufficient receptor for Vms1 localization to mitochondria.
Having observed that EP binds the MTD to enable Vms1 localization, which is inhibited by the LRS via direct MTD binding, we wanted to understand the interplay between the LRS, EP, and their apparent competition for MTD interaction. Our biochemical experiments examined the effects of positively and negatively manipulating the LRS/MTD interaction on Vms1 binding to EPcontaining (EP + ) liposomes. We showed that disrupting the MTD/LRS interaction through LRS mutation promoted binding to EP+ liposomes. Conversely, we showed that covalently tethering the LRS and MTD in order to stabilize their interaction reduced binding to EP + liposomes. Lastly, we showed that binding to EP + liposomes caused the partial dissociation of the LRS from the MTD. Altogether, these biochemical assays indicate that the LRS and EP compete for binding to the MTD and that this interplay is crucial for the regulation of Vms1 mitochondrial localization.
Overall, these data support a model wherein, under basal conditions, Vms1 is ''locked'' in a cytosolic conformation through intramolecular interactions between the LRS and MTD (Movie S1). The low EP abundance on the mitochondrial surface in basal conditions is insufficient to disrupt this intramolecular LRS-MTD interaction. However, mitochondrial perturbation (via rapamycin, H 2 O 2 , antimycin/oligomycin, paraquat, and DMNQ) elicits the production of ROS that generate mitochondrial EP through direct, non-enzymatic modification of ergosterol. This increased EP abundance subsequently competes with the LRS for Vms1 MTD binding, thereby driving Vms1 to localize to stressed mitochondria. This mechanism would enable the rapid recruitment of the Vms1 quality control system to mitigate or repair damaged mitochondria.
Initially, it was quite surprising that EP conferred specificity for Vms1 mitochondrial localization, because its precursor, ergosterol, is more abundant in other cellular membranes (Zinser et al., 1991) . In contrast, however, we found that EP is highly enriched in mitochondria. A likely explanation for the mitochondrial specificity of EP is that it is the product of non-enzymatic oxidation of ergosterol by ROS, particularly by singlet oxygen, and mitochondria are the major source of cellular ROS, which is a natural byproduct of mitochondrial respiration (Balaban et al., 2005) . Moreover, ROS half-lives are typically very short (10 À9 -10 À5 seconds) (Forkink et al., 2010) , which results in a highly localized site of action and production of EP, specifically at damaged mitochondria. An additional potential explanation for mitochondrial specificity is that EP is more rapidly degraded in non-mitochondrial membranes. Indeed, one study showed that the majority of cellular EP is rapidly converted into other oxidized forms of ergosterol by an unidentified EP isomerase (Bö cking et al., 2000) . This isomerase appears to be present in the secretory pathway and, therefore, might degrade EP on most other membranes but not limit the accumulation of mitochondrial EP.
The proposed model is consistent with our finding that Erg2 and Erg3 are essential for efficient Vms1 localization and binding to mitochondria. These enzymes are required for the formation of the 5,7-diene in ergosterol, which is the site of ergosterol that is modified in the conversion to EP. Moreover, erg2D and erg3D mutants exhibited decreased respiratory growth, suggesting that these mutants have defects in mitochondrial respiratory function (Smith and Parks, 1993; Steinmetz et al., 2002) that might be attributed to impaired mitochondrial Vms1 function.
In this study, we consistently observed approximately 2-fold increases of mitochondrial EP abundance and similar augmentation of Vms1 binding to mitochondria and lipids isolated from stressed (rapamycin or H 2 O 2 ) cells. A priori, this relatively small increase in EP abundance might seem insufficient to confer the observed stress-responsive regulation of Vms1 translocation (Heo et al., 2010) , but three issues should be considered. First, the modest increases that we observed in vitro are underestimates, because the mitochondrial isolation procedure itself is stressful and promotes Vms1 translocation (data not shown). Thus, we likely observed an artificially increased basal EP abundance in purified mitochondria, which would diminish the difference in Vms1 binding affinity between mitochondria from stressed and unstressed cells. Second, any membrane architecture and lipid partitioning within the MOM is lost upon extraction and reconstitution for floatation assays. Therefore, any local enrichment of EP, which would be expected based on the behavior of sterols in membranes (Bagnat et al., 2000) , is lost during liposome preparation. Lastly, we suspect that Vms1 is a co-incidence detector and that elevated EP works with another signal to mediate full stress-induced Vms1 translocation. The additional signal(s) might include another specifically induced lipid or other molecule and, at a minimum, likely includes polyubiquitin, which accumulates on damaged mitochondria in the absence of Vms1 (Heo et al., 2010) . For these reasons, the physiological localization of Vms1 to mitochondria in response to stress is expected be more specific and robust than suggested by the limited in vitro effects.
The Vms1 crystal structure revealed the direct interaction between the LRS and MTD domains. Moreover, the structure helped interpret previous mutagenesis data and design new experiments that verify that formation of the Vms1 LRS-MTD interface inhibits mitochondrial localization. These experiments showed that mutation of LRS residues that stabilize the interface results in enhanced mitochondrial localization. Conversely, mutation of MTD residues that stabilize the Vms1 LRS-MTD interface reduce mitochondrial localization, indicating that these residues also participate in binding to mitochondria. The structure also raises several important questions. First, what is the disposition of the LRS when Vms1 is bound to mitochondria? Our data indicate that the LRS dissociates from the MTD but that the multiple hydrophobic LRS residues that are buried against the MTD in the cytosolic conformation are unlikely to become exposed to the cytoplasm. One attractive possibility is that the highly amphipathic LRS helix binds non-specifically to the mitochondrial membrane, as has been extensively characterized in other systems (Aberle et al., 2015) . In this model, the energetic costs of displacing the hydrophobic LRS interaction-which, based on the structure, is expected to be considerable-would be offset by the recovery of hydrophobic interactions of the LRS (and, presumably, the MTD) with the membrane. Another critical question is: what is the structure of the MTD when bound to an EP + membrane? Because the surface of MTD covered by the LRS is large (1,205 Å 2 ), and because some of the MTD residues that we have shown are important for localization to mitochondria are exposed and do not make direct contact with the LRS or stabilize the MTD-LRS interaction, the interaction surface between MTD and mitochondria is likely to be considerable and/or involve a major conformational change. A structure of Vms1 bound to EP is an urgent, if challenging, goal for future studies.
We suspect that analogous lipid oxidation-based stress response mechanisms exist in higher eukaryotes. Based on the high degree of evolutionary conservation in VMS1 across eukaryotes, particularly in the MTD, it is likely that mammalian Vms1 also interacts with an oxidized sterol to mediate mitochondrial quality control. Similarly, damaged chloroplasts produce singlet oxygen, which induces localized lipid peroxidation, subsequent ubiquitylation, and eventual removal of the organelle (Woodson, 2016; Woodson et al., 2015) , which may be mediated by Vms1 or Vms1-like molecules. Therefore, we postulate that sterol oxidation might be a conserved signal of damage to engage quality control systems, including those reliant on Vms1, at organelles under oxidative stress.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: quantify abundance (Khedr and Sheha, 2003) . For EP quantification, we ran a dilution series of commercial EP and quantified each standard spot on the TLC using ImageJ. Using these values, we generated standard curves with R 2 values R 0.97, suggesting that dilutions of the EP standards can be accurately quantified using TLC. We then quantified our unknown samples at a dilution where the EP band was in the linear range of our standard curve.
Silica chromatography
Starting at the base of the column, a classic preparative chromatography column (with solvent reservoir) was prepared with a glass wool plug, washed sand (Fisher Scientific), silica gel (VWR International #SX0143U-1) at a ratio of 50:1 silica mass:sample mass that had been suspended in hexane (Sigma), and another layer of washed sand on top. The hexane was drained from the column and the lipid mixture, resuspended in hexane, was loaded slowly on to the column and allowed to migrate through the sand into the silica gel layer. Lipids were eluted with the following solvent system: 1 column volume hexane (Sigma), 2 column volumes dichloromethane (Fisher Scientific), 2 column volumes of 1:1 dichloromethane:chloroform (Fisher Scientific), and then chloroform until the desired C 28 H 44 O 3 had completely eluted as monitored by TLC.
NMR 1-H NMR spectra were acquired with CDCl 3 (deutered chloroform) as the solvent on a Varian Inova 500 MHz NMR spectrometer in the University of Utah NMR Core Facility.
Lipid blot 1 mL of a lipid solution, containing lipids purified from yeast, EP (Chemfaces #CFN98035), or ergosterol (Fisher Scientific #AC11781), in 100% chloroform was spotted on to nitrocellulose membrane (Fisher Scientific #10600002). The membrane was blocked with 3% fatty-acid free BSA (Sigma #A6003) in TBS (25 mM Tris, 150 mM NaCl, pH 7.5) for one hour at room temperature. The blocking solution was replaced with a 1 mg/mL solution of His 12 -Vms1 1-417 -HA in TBS with 3% fatty-acid free BSA and incubated overnight at 4 C. The membrane was then subjected to standard western blot techniques with 1 and 2 antibody incubation in TBS with 3% fattyacid free BSA to visualize protein-lipid binding.
Liposome preparation
A control lipid solution was prepared by mixing 0.82 molar equivalents of DOPC (Avanti #850375P) and 0.18 molar equivalents of cholesterol (Avanti #700000P) in a glass vial. Additional lipids were added to the control liposome solution where indicated. Solvent was evaporated by gentle vortexing under a steady stream of argon gas to make a lipid film around the walls of the vial. These films were dried under vacuum for one hour at À52 C. The lipid film was then resolubilized in hexane (Sigma) and subsequently evaporated under a gentle stream of argon while vortexing, followed by a second round of vacuum-drying for three to four hours at À52 C. Lipid films were then hydrated with TBS to produce a 1mg lipid/mL buffer mixture. This mixture was rotated overnight at 4 C and extruded through 1.0 mM membranes (Fisher Scientific #05-71-5120) to produce a semi-homogeneous liposome population. Aliquots were stored at À80 C. Liposomes prepared from total mitochondrial lipids were prepared without the addition of DOPC and cholesterol. Total mitochondrial lipids isolated from the indicated strains and additional lipids, if indicated, were mixed and dissolved in chloroform. Liposomes were prepared from this lipid solution as described above.
Liposome floatation assay 100 mL of liposomes were incubated with 2.5 mg of purified Vms1 protein at 4 C for one hour. 10 mL of the mixture was taken as an input control and mixed 1:1 with 4X laemmeli buffer (40% glycerol, 250 mM Tris-HCl pH 6.8, 8%SDS, 0.04% bromophenol blue, 0.1M DTT). 300 mL of 2M sucrose in TBS was added to the liposome-protein mixture and mixed well. A step-sucrose gradient was then created by gently loading 300 mL of 1M sucrose in TBS on top of the liposome mixture, followed by 300 mL of 0.5 M sucrose in TBS, and finally 75 mL of TBS. This was spun for 30 minutes in a Beckman Optima-Max table-top ultracentrifuge at 55,000 rpm allowing the liposomes to float to the top of the gradient, thereby separating unbound protein from liposome-bound protein (Koirala et al., 2013) . 150 mL was taken from the top (bound Vms1) and bottom (unbound Vms1) of the sucrose gradient and analyzed by SDS-PAGE and western blot with a-His 6 antibody (Clontech #631212).
Microscopy
The WT (JRY2509) or mutant strains were transformed with a plasmid expressing Vms1 MTD -GFP (or point mutants) under the native VMS1 promoter and a plasmid expressing mitochondria-targeted RFP. The cells were grown to mid-log phase and then imaged using a Zeiss Axioplan 2 Imaging microscope (Carl Zeiss). To test the effect of statin-treatment on Vms1 MTD localization, WT cells transformed with a plasmid expressing Vms1 MTD -GFP under the native VMS1 promoter and a plasmid expressing mitochondria-targeted RFP were inoculated, back-diluted, and grown in media containing vehicle or 500 mM mevastatin (Santa Cruz Biotech #SC-200853A) for 24 hours prior to imaging. To test the dependence of Vms1 lipid receptor production on the presence of oxygen, WT (JRY2509) cells were transformed with a plasmid expressing Vms1 MTD -GFP under the native VMS1 promoter and a plasmid expressing mitochondria-targeted RFP. After reaching mid-log phase, these cells were grown for 6 hours either in anoxia or normoxia with
